STAT2-dependent induction of RNA adenosine deaminase ADAR1 by type I interferon differs between mouse and human cells in the requirement for STAT1

Virology

Volumn 485, Issue , 2015, Pages 363-370

  George, Cyril X ^a   Samuel, Charles E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adenosine deaminase acting on RNA (ADAR); Innate immunity; Interferon (IFN); Signal transducers and activators of transcription (STAT)

Indexed keywords

ADENOSINE DEAMINASE; ADENOSINE DEAMINASE ACTING ON RNA1; INTERFERON; INTERFERON REGULATORY FACTOR 9; MICROSOMAL AMINOPEPTIDASE; STAT1 PROTEIN; STAT2 PROTEIN; UNCLASSIFIED DRUG; MESSENGER RNA; PROTEIN BINDING;

2FTGH CELL; ANIMAL CELL; ARTICLE; CELL LINE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME INDUCTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MEF CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; U3A CELL; U6A CELL; ANIMAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENETICS; METABOLISM;

ADENOSINE DEAMINASE; ANIMALS; CELL LINE; GENE EXPRESSION REGULATION; GENE KNOCKOUT TECHNIQUES; HUMANS; INTERFERON TYPE I; MICE; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RNA, MESSENGER; STAT1 TRANSCRIPTION FACTOR; STAT2 TRANSCRIPTION FACTOR; TRANSCRIPTIONAL ACTIVATION;

EID: 84940832694     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2015.08.001     Document Type: Article

References (52)

1. Ashour J., Morrison J., Laurent-Rolle M., Belicha-Villanueva A., Plumlee C.R., Bernal-Rubio D., Williams K.L., Harris E., Fernandez-Sesma A., Schindler C., Garcia-Sastre A. Mouse STAT2 restricts early dengue virus replication. Cell Host Microbe 2010, 8:410-421.
2. Bass B.L. RNA editing by adenosine deaminases that act on RNA. Annu. Rev. Biochem. 2002, 71:817-846.
3. Blaszczyk K., Olejnik A., Nowicka H., Ozgyin L., Chen Y.L., Chmielewski S., Kostyrko K., Wesoly J., Balint B.L., Lee C.K., Bluyssen H.A. STAT2/IRF9 directs a prolonged ISGF3-like transcriptional response and antiviral activity in the absence of STAT1. Biochem. J. 2015, 466:511-524.
4. Borden E.C., Sen G.C., Uze G., Silverman R.H., Ransohoff R.M., Foster G.R., Stark G.R. Interferons at age 50: past, current and future impact on biomedicine. Nat. Rev. Drug Discovery 2007, 6:975-990.
5. Das S., Ward S.V., Tacke R.S., Suske G., Samuel C.E. Activation of the RNA-dependent protein kinase PKR promoter in the absence of interferon is dependent upon Sp proteins. J. Biol. Chem. 2006, 281:3244-3253.
6. Durbin J.E., Hackenmiller R., Simon M.C., Levy D.E. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 1996, 84:443-450.
7. Gelinas J.F., Clerzius G., Shaw E., Gatignol A. Enhancement of replication of RNA viruses by ADAR1 via RNA editing and inhibition of RNA-activated protein kinase. J. Virol. 2011, 85:8460-8466.
8. George C.X., Das S., Samuel C.E. Organization of the mouse RNA-specific adenosine deaminase Adar1 gene 5'-region and demonstration of STAT1-independent, STAT2-dependent transcriptional activation by interferon. Virology 2008, 380:338-343.
9. George C.X., Gan Z., Liu Y., Samuel C.E. Adenosine deaminases acting on RNA, RNA editing, and interferon action. J. Interferon Cytokine Res. 2011, 31:99-117.
10. George C.X., Samuel C.E. Characterization of the 5'-flanking region of the human RNA-specific adenosine deaminase ADAR1 gene and identification of an interferon-inducible ADAR1 promoter. Gene 1999, 229:203-213.
11. George C.X., Samuel C.E. Human RNA-specific adenosine deaminase ADAR1 transcripts possess alternative exon 1 structures that initiate from different promoters, one constitutively active and the other interferon inducible. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:4621-4626.
12. George C.X., Wagner M.V., Samuel C.E. Expression of interferon-inducible RNA adenosine deaminase ADAR1 during pathogen infection and mouse embryo development involves tissue-selective promoter utilization and alternative splicing. J. Biol. Chem. 2005, 280:15020-15028.
13. Hahm B., Trifilo M.J., Zuniga E.I., Oldstone M.B. Viruses evade the immune system through type I interferon-mediated STAT2-dependent, but STAT1-independent, signaling. Immunity 2005, 22:247-257.
14. Hartner J.C., Schmittwolf C., Kispert A., Muller A.M., Higuchi M., Seeburg P.H. Liver disintegration in the mouse embryo caused by deficiency in the RNA-editing enzyme ADAR1. J. Biol. Chem. 2004, 279:4894-4902.
15. Hartner J.C., Walkley C.R., Lu J., Orkin S.H. ADAR1 is essential for the maintenance of hematopoiesis and suppression of interferon signaling. Nat. Immunol. 2009, 10:109-115.
16. John J., McKendry R., Pellegrini S., Flavell D., Kerr I.M., Stark G.R. Isolation and characterization of a new mutant human cell line unresponsive to alpha and beta interferons. Mol. Cell Biol. 1991, 11:4189-4195.
17. John L., Samuel C.E. Induction of stress granules by interferon and down-regulation by the cellular RNA adenosine deaminase ADAR1. Virology 2014, 454-455:299-310.
18. Kimura T., Kadokawa Y., Harada H., Matsumoto M., Sato M., Kashiwazaki Y., Tarutani M., Tan R.S., Takasugi T., Matsuyama T., Mak T.W., Noguchi S., Taniguchi T. Essential and non-redundant roles of p48 (ISGF3 gamma) and IRF-1 in both type I and type II interferon responses, as revealed by gene targeting studies. Genes Cells 1996, 1:115-124.
19. Kraus T.A., Lau J.F., Parisien J.P., Horvath C.M. A hybrid IRF9-STAT2 protein recapitulates interferon-stimulated gene expression and antiviral response. J. Biol. Chem. 2003, 278:13033-13038.
20. Levy D.E., Lew D.J., Decker T., Kessler D.S., Darnell J.E. Synergistic interaction between interferon-alpha and interferon-gamma through induced synthesis of one subunit of the transcription factor ISGF3. EMBO J. 1990, 9:1105-1111.
21. Li Z., Okonski K.M., Samuel C.E. Adenosine deaminase acting on RNA 1 (ADAR1) suppresses the induction of interferon by measles virus. J. Virol. 2012, 86:3787-3794.
22. Livingston J.H., Lin J.P., Dale R.C., Gill D., Brogan P., Munnich A., Kurian M.A., Gonzalez-Martinez V., De Goede C.G., Falconer A., Forte G., Jenkinson E.M., Kasher P.R., Szynkiewicz M., Rice G.I., Crow Y.J. A type I interferon signature identifies bilateral striatal necrosis due to mutations in ADAR1. J. Med. Genet. 2014, 51:76-82.
23. Lou Y.J., Zhang Z.L., Pan X.R., Xu G.P., Jia P.M., Li D., Tong J.H. Intact JAK-STAT signaling pathway is a prerequisite for STAT1 to reinforce the expression of RIG-G gene. Exp. Cell Res. 2011, 317:513-520.
24. Mannion N.M., Greenwood S.M., Young R., Cox S., Brindle J., Read D., Nellaker C., Vesely C., Ponting C.P., McLaughlin P.J., Jantsch M.F., Dorin J., Adams I.R., Scadden A.D., Ohman M., Keegan L.P., O'Connell M.A. The RNA-editing enzyme ADAR1 controls innate immune responses to RNA. Cell Rep. 2014, 9:1482-1494.
25. Mateo M., Navaratnarajah C.K., Willenbring R.C., Maroun J.W., Iankov I., Lopez M., Sinn P.L., Cattaneo R. Different roles of the three loops forming the adhesive interface of nectin-4 in measles virus binding and cell entry, nectin-4 homodimerization, and heterodimerization with nectin-1. J. Virol. 2014, 88:14161-14171.
26. McAllister C.S., Taghavi N., Samuel C.E. Protein kinase PKR amplification of interferon beta induction occurs through initiation factor eIF-2alpha-mediated translational control. J. Biol. Chem. 2012, 287:36384-36392.
27. McKendry R., John J., Flavell D., Muller M., Kerr I.M., Stark G.R. High-frequency mutagenesis of human cells and characterization of a mutant unresponsive to both alpha and gamma interferons. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:11455-11459.
28. Meraz M.A., White J.M., Sheehan K.C., Bach E.A., Rodig S.J., Dighe A.S., Kaplan D.H., Riley J.K., Greenlund A.C., Campbell D., Carver-Moore K., DuBois R.N., Clark R., Aguet M., Schreiber R.D. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 1996, 84:431-442.
29. Okonski K.M., Samuel C.E. Stress granule formation induced by measles virus is protein kinase PKR dependent and impaired by RNA adenosine deaminase ADAR1. J. Virol. 2013, 87:756-766.
30. Ousman S.S., Wang J., Campbell I.L. Differential regulation of interferon regulatory factor (IRF)-7 and IRF-9 gene expression in the central nervous system during viral infection. J. Virol. 2005, 79:7514-7527.
31. Parisien J.P., Lau J.F., Horvath C.M. STAT2 acts as a host range determinant for species-specific paramyxovirus interferon antagonism and simian virus 5 replication. J. Virol. 2002, 76:6435-6441.
32. Park C., Li S., Cha E., Schindler C. Immune response in Stat2 knockout mice. Immunity 2000, 13:795-804.
33. Patterson J.B., Samuel C.E. Expression and regulation by interferon of a double-stranded-RNA-specific adenosine deaminase from human cells: evidence for two forms of the deaminase. Mol. Cell Biol. 1995, 15:5376-5388.
34. Patterson J.B., Thomis D.C., Hans S.L., Samuel C.E. Mechanism of interferon action: double-stranded RNA-specific adenosine deaminase from human cells is inducible by alpha and gamma interferons. Virology 1995, 210:508-511.
35. Perry S.T., Buck M.D., Lada S.M., Schindler C., Shresta S. STAT2 mediates innate immunity to Dengue virus in the absence of STAT1 via the type I interferon receptor. PLoS Pathog. 2011, 7:e1001297.
36. Pfaller C.K., Mastorakos G.M., Matchett W.E., Ma X., Samuel C.E., Cattaneo R. Measles virus defective-interfering RNAs are generated frequently and early in the absence of C protein and can be destabilized by adenosine deaminase acting on RNA 1-like hypermutations. J. Virol. 2015, 89:7735-7747.
37. Platanias L.C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 2005, 5:375-386.
38. Pulit-Penaloza J.A., Scherbik S.V., Brinton M.A. Activation of Oas1a gene expression by type I IFN requires both STAT1 and STAT2 while only STAT2 is required for Oas1b activation. Virology 2012, 425:71-81.
39. Randall R.E., Goodbourn S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J. Gen. Virol. 2008, 89:1-47.
40. Rice G.I., Kasher P.R., Forte G.M., Mannion N.M., Greenwood S.M., Szynkiewicz M., Dickerson J.E., Bhaskar S.S., Zampini M., Briggs T.A., Jenkinson E.M., Bacino C.A., Battini R., Bertini E., Brogan P.A., Brueton L.A., Carpanelli M., De Laet C., de Lonlay P., del Toro M., Desguerre I., Fazzi E., Garcia-Cazorla A., Heiberg A., Kawaguchi M., Kumar R., Lin J.P., Lourenco C.M., Male A.M., Marques W., Mignot C., Olivieri I., Orcesi S., Prabhakar P., Rasmussen M., Robinson R.A., Rozenberg F., Schmidt J.L., Steindl K., Tan T.Y., van der Merwe W.G., Vanderver A., Vassallo G., Wakeling E.L., Wassmer E., Whittaker E., Livingston J.H., Lebon P., Suzuki T., McLaughlin P.J., Keegan L.P., O'Connell M.A., Lovell S.C., Crow Y.J. Mutations in ADAR1 cause Aicardi-Goutieres syndrome associated with a type I interferon signature. Nat. Genet. 2012, 44:1243-1248.
41. Samuel C.E. Antiviral actions of interferons. Clin. Microbiol. Rev. 2001, 14:778-809.
42. Samuel C.E. Adenosine deaminases acting on RNA (ADARs) are both antiviral and proviral. Virology 2011, 411:180-193.
43. Schindler C., Levy D.E., Decker T. JAK-STAT signaling: from interferons to cytokines. J. Biol. Chem. 2007, 282:20059-20063.
44. Schoggins J.W., MacDuff D.A., Imanaka N., Gainey M.D., Shrestha B., Eitson J.L., Mar K.B., Richardson R.B., Ratushny A.V., Litvak V., Dabelic R., Manicassamy B., Aitchison J.D., Aderem A., Elliott R.M., Garcia-Sastre A., Racaniello V., Snijder E.J., Yokoyama W.M., Diamond M.S., Virgin H.W., Rice C.M. Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity. Nature 2014, 505:691-695.
45. Stark G.R., Darnell J.E. The JAK-STAT pathway at twenty. Immunity 2012, 36:503-514.
46. Taghavi N., Samuel C.E. Protein kinase PKR catalytic activity is required for the PKR-dependent activation of mitogen-activated protein kinases and amplification of interferon beta induction following virus infection. Virology 2012, 427:208-216.
47. Toth A.M., Li Z., Cattaneo R., Samuel C.E. RNA-specific adenosine deaminase ADAR1 suppresses measles virus-induced apoptosis and activation of protein kinase PKR. J. Biol. Chem. 2009, 284:29350-29356.
48. Toth A.M., Zhang P., Das S., George C.X., Samuel C.E. Interferon action and the double-stranded RNA-dependent enzymes ADAR1 adenosine deaminase and PKR protein kinase. Prog. Nucleic Acid Res. Mol. Biol. 2006, 81:369-434.
49. Wang Q., Miyakoda M., Yang W., Khillan J., Stachura D.L., Weiss M.J., Nishikura K. Stress-induced apoptosis associated with null mutation of ADAR1 RNA editing deaminase gene. J. Biol. Chem. 2004, 279:4952-4961.
50. Ward S.V., George C.X., Welch M.J., Liou L.Y., Hahm B., Lewicki H., de la Torre J.C., Samuel C.E., Oldstone M.B. RNA editing enzyme adenosine deaminase is a restriction factor for controlling measles virus replication that also is required for embryogenesis. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:331-336.
51. Ward S.V., Samuel C.E. The PKR kinase promoter binds both Sp1 and Sp3, but only Sp3 functions as part of the interferon-inducible complex with ISGF-3 proteins. Virology 2003, 313:553-566.
52. Zhang J.Y., Chen X.D., Zhang Z., Wang H.L., Guo L., Liu Y., Zhao X.Z., Cao W., Xing Q.H., Shao F.M. The adenosine deaminase acting on RNA 1 p150 isoform is involved in the pathogenesis of dyschromatosis symmetrica hereditaria. Br. J. Dermatol. 2013, 169:637-644.